PMID- 26109870
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150625
LR  - 20200930
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 8
DP  - 2015
TI  - Bortezomib-based vs non-bortezomib-based post-transplantation treatment in 
      multiple myeloma patients: a systematic review and meta-analysis of Phase III 
      randomized controlled trials.
PG  - 1459-69
LID - 10.2147/OTT.S84828 [doi]
AB  - OBJECTIVE: To evaluate the efficacy and safety of bortezomib-based vs 
      non-bortezomib-based post-transplantation therapy in patients with multiple 
      myeloma. METHODS: Data of relevant randomized controlled trials assessing the 
      effect of bortezomib as post-transplantation consolidation or maintenance therapy 
      was obtained through a comprehensive search. The outcome measures included 
      response rate, progression-free survival, overall survival, and adverse events 
      (AEs). The hazard ratio (HR), Cochran-Mantel-Haenszel odds ratio (OR), and 95% 
      confidence interval (95% CI) were applied to evaluate the effect of bortezomib in 
      relation to the end points such as progression-free survival, overall survival, 
      response rate, and AEs. RESULTS: Three randomized controlled trials comprising 
      1,518 participants were included in this study. Pooled ORs for the rates of 
      overall response, and complete response and near complete response, were 1.85 and 
      1.75, respectively. Pooled HR for progression-free survival favored 
      bortezomib-based therapy over non-bortezomib-based therapy (0.73, 95% CI: 
      0.67-0.81), while no statistically significant difference could be found between 
      the two groups regarding the pooled HR for 3-year overall survival. Moreover, 
      incidence rates of overall adverse events and grade 3 and 4 peripheral neuropathy 
      were similar in the bortezomib-based groups and the non-bortezomib-based groups 
      (P=0.12 and P=0.41, respectively). The corresponding cumulative meta-analyses of 
      the rates of overall response rate, complete response and near complete response, 
      and grades 3 and 4 peripheral neuropathy supported the superiority of 
      bortezomib-based maintenance therapy over consolidation therapy. CONCLUSION: 
      Bortezomib-based therapy after autologous stem cell transplantation, with 
      tolerable AEs, could obviously improve the response as well as the outcome of 
      multiple myeloma patients, particularly when bortezomib was administered as 
      maintenance therapy.
FAU - Liu, Xiaoping
AU  - Liu X
AD  - Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 
      People's Republic of China.
FAU - He, Colin K
AU  - He CK
AD  - Orient Health Care, NYC, USA.
FAU - Meng, Xiangyu
AU  - Meng X
AD  - Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 
      People's Republic of China.
FAU - He, Li
AU  - He L
AD  - Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 
      People's Republic of China.
FAU - Li, Kaili
AU  - Li K
AD  - Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 
      People's Republic of China.
FAU - Liang, Qing
AU  - Liang Q
AD  - Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 
      People's Republic of China.
FAU - Shao, Liang
AU  - Shao L
AD  - Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 
      People's Republic of China.
FAU - Liu, Shangqin
AU  - Liu S
AD  - Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20150615
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC4474400
OTO - NOTNLM
OT  - bortezomib-based regimen
OT  - multiple myeloma
OT  - post-transplantation therapy
EDAT- 2015/06/26 06:00
MHDA- 2015/06/26 06:01
PMCR- 2015/06/15
CRDT- 2015/06/26 06:00
PHST- 2015/06/26 06:00 [entrez]
PHST- 2015/06/26 06:00 [pubmed]
PHST- 2015/06/26 06:01 [medline]
PHST- 2015/06/15 00:00 [pmc-release]
AID - ott-8-1459 [pii]
AID - 10.2147/OTT.S84828 [doi]
PST - epublish
SO  - Onco Targets Ther. 2015 Jun 15;8:1459-69. doi: 10.2147/OTT.S84828. eCollection 
      2015.